New genetic biomarkers predicting 5-aminosalicylate-induced adverse events in patients with inflammatory bowel diseases.
In: Therapeutic Advances in Gastroenterology, 2024-01-27, S. 1-10
Online
academicJournal
Zugriff:
Background: Notably, 5-aminosalicylates (5-ASA) are vital in treating inflammatory bowel diseases (IBD). The adverse events of 5-ASA rarely occur but they could be fatal. Objectives: We aimed to discover new genetic biomarkers predicting 5-ASA-induced adverse events in patients with IBD. Design: This was a retrospective observational study. Methods: We performed a genome-wide association study on patients with IBD in South Korea. We defined subset 1 as 39 all adverse events and 272 controls; subset 2 as 20 severe adverse events and 291 controls (mild adverse events and control); subset 3 as 20 severe adverse events and 272 controls; and subset 4 as 19 mild adverse events and 272 controls. Logistic regression analysis was performed and commonly found associated genes were determined as candidate single-nucleotide polymorphisms predicting 5-ASA adverse events. Results: Patients with Crohn's disease (CD) were significantly negatively associated with the development of adverse events compared to patients with ulcerative colitis (UC) (5.3% versus 22.9%). However, sex and age at diagnosis were unassociated with the adverse events of 5-ASA. rs13898676 [odds ratio (OR), 20.33; 95% confidence interval (CI), 5.69–72.67; p = 3.57 × e −6 ], rs12681590 (OR, 7.35; 95% CI, 2.85–19.00; p = 3.78 × e −5 ), rs10967320 (OR, 4.51; 95% CI, 2.18–9.31; p = 4.72 × e −5 ), and rs78726924 (OR, 3.54; 95% CI, 1.69–7.40; p = 7.96 × e −5 ) were genetic biomarkers predicting 5-ASA-induced severe adverse events in patients with IBD. Conclusion: The adverse events of 5-ASA were more common in patients with UC than those with CD in our study. We found that novel rs13898676 nearby WSB2 was the most significant genetic locus contributing to 5-ASA's adverse event risk. [ABSTRACT FROM AUTHOR]
Copyright of Therapeutic Advances in Gastroenterology is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
New genetic biomarkers predicting 5-aminosalicylate-induced adverse events in patients with inflammatory bowel diseases.
|
---|---|
Autor/in / Beteiligte Person: | Park, Jihye ; Park, I. Seul ; Kim, Ji Hyung ; Ji, Jung Hyun ; Park, Soo Jung ; Park, Jae Jun ; Kim, Tae Il ; Kim, Seung Won ; Cheon, Jae Hee |
Link: | |
Zeitschrift: | Therapeutic Advances in Gastroenterology, 2024-01-27, S. 1-10 |
Veröffentlichung: | 2024 |
Medientyp: | academicJournal |
ISSN: | 1756-283X (print) |
DOI: | 10.1177/17562848241227029 |
Schlagwort: |
|
Sonstiges: |
|